Cipla, a leading pharmaceutical company, reported a 3.73% increase in net profit for Q2FY26, reaching a record high of Rs 1,351.17 crore. Revenue from product sales also saw a significant rise of 6.98% YoY. The company’s EBITDA margin remained stable at 25%.